These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 31215815

  • 1. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy.
    Yang J, Gao J.
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):723-728. PubMed ID: 31215815
    [Abstract] [Full Text] [Related]

  • 2. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM.
    CNS Drugs; 2023 Nov; 37(11):1009-1020. PubMed ID: 37847434
    [Abstract] [Full Text] [Related]

  • 3. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y, Shapiro C, Mayer G, Lammers GJ, Emsellem H, Plazzi G, Chen D, Carter LP, Lee L, Black J, Thorpy MJ.
    CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
    [Abstract] [Full Text] [Related]

  • 4. Solriamfetol: First Global Approval.
    Markham A.
    Drugs; 2019 May; 79(7):785-790. PubMed ID: 31062265
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
    Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK.
    Sleep Med; 2020 Nov; 75():510-521. PubMed ID: 33032062
    [Abstract] [Full Text] [Related]

  • 6. A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
    Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y.
    Ann Neurol; 2019 Mar; 85(3):359-370. PubMed ID: 30694576
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
    Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP, TONES 3 Study Investigators.
    Am J Respir Crit Care Med; 2019 Jun 01; 199(11):1421-1431. PubMed ID: 30521757
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
    Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A.
    J Clin Sleep Med; 2022 Jan 01; 18(1):235-244. PubMed ID: 34283019
    [Abstract] [Full Text] [Related]

  • 12. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea.
    Abad VC, Guilleminault C.
    Expert Rev Respir Med; 2018 Dec 01; 12(12):1007-1019. PubMed ID: 30365900
    [Abstract] [Full Text] [Related]

  • 13. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
    Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R.
    Sleep; 2020 Feb 13; 43(2):. PubMed ID: 31691827
    [Abstract] [Full Text] [Related]

  • 14. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
    Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G, Chen D, Carter LP, Villa KF, Lee L, Menno D, Black J, Dauvilliers Y.
    Sleep Med; 2020 Mar 13; 67():128-136. PubMed ID: 31926465
    [Abstract] [Full Text] [Related]

  • 15. A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness.
    Fuller MC, Carlson S, Pysick H, Berry V, Tondryk A, Swartz H, Cornett EM, Kaye AM, Viswanath O, Urits I, Kaye AD.
    Psychopharmacol Bull; 2024 Mar 04; 54(1):65-86. PubMed ID: 38449471
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials.
    Wang J, Yang S, Li X, Wang T, Xu Z, Xu X, Gao H, Chen G.
    Sleep Med; 2021 Mar 04; 79():40-47. PubMed ID: 33472129
    [Abstract] [Full Text] [Related]

  • 18. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.
    Rosenberg R, Baladi M, Bron M.
    J Clin Sleep Med; 2021 Apr 01; 17(4):711-717. PubMed ID: 33226332
    [Abstract] [Full Text] [Related]

  • 19. Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy.
    Thorpy MJ, Hyman D, Parks GS, Chen A, Foley C, Baldys B, Ito D, Singh H.
    Clin Ther; 2022 Oct 01; 44(10):1356-1369. PubMed ID: 36171171
    [Abstract] [Full Text] [Related]

  • 20. Solriamfetol (Sunosi) for excessive daytime sleepiness.
    Med Lett Drugs Ther; 2019 Aug 26; 61(1579):132-134. PubMed ID: 31581157
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.